Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

By Kishiki Tomokazu   Ohnishi Hiroaki   Masaki Tadahiko   Ohtsuka Kouki   Ohkura Yasuo   Furuse Jyunji   Watanabe Takashi   Sugiyama Masanori  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature

By Moroni Mauro  

Targeted Oncology, Vol. 3, Iss. 2, 2008-04 ,pp. : 127-130

Springer Publishing Company

Access to resources Recommend Favorite

EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 1, Iss. 2, 2006-06 ,pp. : 209-222

Bentham Science Publishers

Access to resources Recommend Favorite

Association between codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis

By Chen Jian   Ye Yun   Sun Haozhen   Shi Genming  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 265-272

Springer Publishing Company

Access to resources Recommend Favorite